U.S. Interventional Cardiology And Peripheral Market To Reach $13.1 Billion By 2033

U.S. Interventional Cardiology and Peripheral Market Growth & Trends

The U.S. interventional cardiology and peripheral market size is anticipated to reach USD 13.1 billion by 2033, growing at a CAGR of 5.8% from 2025 to 2033, according to a new report by Grand View Research, Inc. The market is driven by the growing burden of cardiovascular & peripheral vascular diseases, rising preference for minimally invasive procedures, and continuous advancements in device technology. Increasing geriatric population, higher rates of diabetes & hypertension, and supportive reimbursement policies further fuel market expansion.

The increasing incidence of cardiovascular conditions contributes to sustained growth in the interventional cardiology and peripheral market. A wide range of patients are being diagnosed with coronary and peripheral arterial blockages at various stages, prompting timely medical intervention. As disease detection improves through diagnostic advancements and routine check-ups, there is greater emphasis on early and less invasive treatment pathways.

Interventional procedures such as angioplasty, stenting, and thrombectomy are now central to managing these conditions effectively. In October 2024, the CDC reported that heart disease remained the leading cause of death in the U.S., responsible for 702,880 deaths in 2022, equivalent to one in every five deaths. Coronary artery disease (CAD) was the most common form, killing over 371,000 people. Risk factors such as high blood pressure, high cholesterol, smoking, diabetes, obesity, and physical inactivity were identified as major contributors.

 Request a free sample copy or view report summary: U.S. Interventional Cardiology And Peripheral Market Report

U.S. Interventional Cardiology And Peripheral Market Report Highlights

• Coronary stents led the U.S. interventional cardiology and peripheral market. They accounted for a share of 41.5% in 2024, fueled by technological advancements, rising cardiovascular disease prevalence, and increased use of minimally invasive procedures.

• Based on application, the angioplasty segment accounted for the largest revenue share of 59.2% in 2024. The significant growth of this segment is largely driven by the high prevalence of atherosclerotic cardiovascular disease, increasing use of drug-eluting balloons & stents, and rising demand for minimally invasive revascularization procedures.

• Emerging players are adopting diverse strategies, such as new product launches, to strengthen their market presence.

• In February 2024, Biotronik launched the Micro Rx catheter in the U.S. to support guidewire procedures during PCI, reflecting ongoing technological progress and sustained market growth.

U.S. Interventional Cardiology And Peripheral Market Segmentation

Grand View Research has segmented the U.S. interventional cardiology and peripheral market report based on product, and application:

U.S. Interventional Cardiology And Peripheral Product Outlook (Revenue, USD Million, 2021 - 2033)

• Interventional Catheters

• Microcatheters

  • Support Microcatheters

  • Delivery Microcatheters

  • Others

• Guidewires

• Peripheral Stents

  • Self-expanding

  • Balloon-expandable

  • Drug-eluting Stents

• Coronary Stents

  • Bioabsorbable Stents

  • Drug-Eluting Stents

  • Bare Metal Stents

• PTCA Balloon Catheters

• Atherectomy Devices

• Chronic Total Occlusion Devices

• Synthetic Surgical Grafts

• Embolic Protection Devices

• IVC Filters

• PTA Balloon Catheters

• Thrombectomy Devices

U.S. Interventional Cardiology And Peripheral Application Outlook (Revenue, USD Million, 2021 - 2033)

• Angioplasty

• Congenital Heart Defect Correction

• Thrombectomy

• Valvuloplasty

• Percutaneous Valve Repair

• Others

List of Key Players of U.S. Interventional Cardiology & Peripheral Market

• B. Braun SE

• BD

• Cardinal Health

• Medtronic

• Teleflex Incorporated

• W. L. Gore & Associates Inc.

• Cook

• Boston Scientific Corporation

• AngioDynamics

• Abbott

• OrbusNeich Medical Group Holdings Limited